Who will get Covid vaccine first? Matt Hancock tells NHS to prepare for jabs from start of December

6.4k

View
comments

More than 1,200 GP surgeries are being geared up to dish out 1.2million doses of a Covid-19 vaccine each week as soon as health chiefs approve a jab, in a major NHS operation to get life back to normal.

Matt Hancock has promised the health service will work around the clock to get the UK vaccinated, with practices open between 8am and 8pm every day of the week and on Bank Holidays. He admitted deploying the vaccine was going to be a ‘colossal challenge’ and revealed the military were on standby to help.

NHS bosses have told all of England’s 1,250 GP networks to designate a single practice capable of administering at least 975 doses of the vaccine in their area each week — the equivalent of at least 1.22million. Surgeries will need to have fridge space available by December 1, according to documents.

Pharmacists and dedicated clinics set up in places such as sports halls are also likely to be used. Patients will need to be observed for 15 minutes after the vaccination is administered and appointments can be managed through a national booking system, it was also revealed today. 

Number 10 has been urged ‘not to screw up’ the rollout of any coronavirus jab, in a stark warning from one of the government’s most prominent scientists on the back of Pfizer’s breakthrough. 

Sir John Bell, regius professor of medicine at Oxford University and a member of Downing St’s vaccine taskforce, said scientists had delivered their end of the bargain by creating a Covid-19 vaccine that exceeded expectations — early data on Pfizer’s jab showed it can prevent nine in 10 people from catching the virus.

But he warned it was now on ministers to hold up their end of the deal by ensuring any approved vaccine is rolled out smoothly to vulnerable groups who are most at risk of falling victim to Covid-19. Care home staff and residents are at the front of the queue. 

Pfizer’s jab — considered the front-runner alongside Oxford’s experimental jab — has to be stored at -70C which rules out keeping it at most GP surgeries or pharmacies. And it needs to be transported in refrigerated lorries and special suitcase-sized boxes filled with dry ice to prevent it from spoiling.  

The Government’s track record in handling logistical issues through the pandemic will not instill confidence that the mass-rollout of the new vaccine will run without any hiccups. For example, the centralised testing programme has been hit by a catalogue of failures since the pandemic began and the contact tracing mobile app was delayed by four months. 

One senior Tory warned that the government faces catastrophic public backlash if it makes a mess of the vaccine rollout. ‘If we get this wrong, we’re toast,’ they told MailOnline. The MP said the Prime Minister should hand the reins to a senior military figure, who should also be the public face of the distribution effort.

They said: ‘If we hadn’t had the military involved someone would still be drawing up outline planning for the Nightingale hospitals. They can set up wards in theatres of war. The military are trusted. They have no axe to grind and they have authority. They are impartial servants of Crown and country.’ 

Sir John told MPs today he expects Brits to get their hands on up to three jabs ‘before New Year’ when data from studies of other promising candidates start to pour in over the coming weeks. 

MailOnline understands Oxford University’s vaccine, which is being manufactured and distributed by Cambridge-based pharma giant AstraZeneca, will publish its preliminary results next week, which will kick-start the rollout process of its candidate. 

The third vaccine most likely to be ready by the year’s end is being made by by US firm Moderna. The MHRA last month put it under a rolling review, which signals it is being earmarked as one of the most promising candidates. 

In more good news Sir John claimed there was an ’80 per cent chance’ life in the UK will be back to normal by spring, provided the Government ‘doesn’t screw up the distribution of the vaccines’. 

In other coronavirus developments today:  

• Experts warned a Covid vaccine won’t immediately bring the pandemic to an end and scientists and officials must be honest about how long it will take to roll one out and get life back to normal;
• Dedicated GP vaccination clinics are planned to be set up to deliver at least 975 doses a week, according to NHS England documents, should a vaccine be approved for use in the UK;
• The Welsh Government says it could start offering a Covid-19 vaccine to those in high risk groups as early as December should a jab pass final safety checks this month; 
• Donald Trump accused the US Food and Drug Administration of deliberately delaying work on a coronavirus vaccination in order to thwart his re-election hopes;
• Brazil suspended clinical trials of a Chinese-developed Covid-19 vaccine after an ‘adverse incident’ involving a volunteer recipient;
• Redundancies hit a new record in the last quarter as unemployment spiked to its highest level in four years amid the coronavirus crisis;
• Mass Covid testing will be rolled out to university students so they can go home for Christmas, it was claimed;
• Traffic levels in London and elsewhere around the country are on the rise despite England’s second lockdown, figures revealed.

Dedicated GP clinics are being set up to deliver coronavirus vaccines across England at a minimum of 975 doses per week each, according to new documents.

NHS England has told England’s 1,250 primary care networks to designate a single practice to administer vaccines in their area capable of delivering vaccines from 8am to 8pm seven days a week, including on bank holidays if needed.

The practices will need to have fridge space available by December 1, and ‘capacity to administer minimum of 975 doses per week or greater’.

Practices will receive a £12.58 payment for each dose of a coronavirus vaccine, meaning they will receive £25.16 for each patient vaccinated in a two-dose course, the document show.

Patients will also need to be observed for 15 minutes after the vaccination is administered, while annual flu jabs and Covid-19 vaccinations must be given at least a week apart. The documents said appointments can be managed through a national booking system.

They said: ‘Once patients are notified by the national call/recall service they are eligible for a vaccination, they would have the choice to book an appointment at a general practice-led vaccination centre or, use the National Booking Service to be vaccinated by another provider.’

Health Secretary Matt Hancock said on Tuesday he expects GPs to play a big role in administering any coronavirus jab. Pharmacists and dedicated clinics set up in places such as sports halls are also likely to be used.

Health officials are gearing up for one of the biggest vaccination programmes in history after Pfizer, the US drugs giant which makes Viagra, published preliminary data yesterday showing its vaccine can protect nine out of 10 people from catching Covid-19, with the full results to be published later this month. 

The breakthrough was the first real ray of hope in the pandemic and could spell an end to the perpetual cycle of locking down and opening up that Britain has been trapped in since March. 

To put it in perspective, the 90 per cent rate makes Pfizer’s jab more effective than vaccines that have been around for decades. The flu jab is between 30 and 60 per cent effective, depending on the strain of the virus each year, whereas for tuberculosis it is between 60 and 80 per cent and HPV is about 60 per cent. If Pfizer’s data is backed up, it would even put it ahead of the measles vaccine, which is about 88 per cent effective. 

A priority list of which Brits should get a vaccine first was drawn up earlier this year by the influential Joint Committee on Vaccination and Immunisation (JCVI) and is now being used as the blueprint for the rollout. 

After care homes are inoculated, NHS staff and everyone over the age of 80 will be second in line. Those over 75 will be next in the queue, followed by over-70s, over-65s and high-risk adults under 65 with diseases such as cancer.

They will be followed by moderate risk adults under 65 – including diabetics and asthmatics. Over-60s will be next, with over-55s and over-50s the final priority groups. The general population will be last to get their hands on a jab and the JCVI says they will be prioritised based on age or underlying conditions.

Experts have said it is worth getting everyone vaccinated against coronavirus with Pfizer’s jab should it be approved, even though early results suggest it doesn’t trigger an immune response in one in ten people, because this will help to protect others and the most vulnerable from the virus. 

They added that in those where the vaccine is unlikely to stop them catching Covid-19 it could still make a severe infection less likely, helping to protect them from being hospitalised and stop the NHS from becoming overwhelmed. 

Sir John, speaking to the House of Commons Science and Technology Committee about Pfizer’s vaccine news today, said: ‘I think this journey to a vaccine has been a long journey and I think there’s a risk that people will underestimate the importance of the announcement yesterday and that is the big challenge here was to find a vaccine that actually had efficacy against this virus. There are many pathogens for which we have looked for decades and not found a vaccine that works.

‘Now are there some more things we need to do? We’ve got to get regulatory approval, we’ve got to get more material to the manufacturer.

‘It’ll be hard to distribute as it has to be distributed at -80C which will be complicated but it also signals I think that many of the other vaccines that have the same immunogenicity are likely also to be efficacious. 

‘So I wouldn’t be surprised if we hit the new year with two or three vaccines, all of which could be distributed.’

He added: ‘And that’s why I’m quite optimistic of getting enough vaccinations done in the first quarter of next year that by spring things will start to look much more normal than they do now.’

Asked how realistic is it to think the UK could be back to normal by the spring, Sir John told MPs: ‘I think we’ve got a 70 to 80 per cent chance of doing that. That’s provided they don’t screw up the distribution of the vaccine, that’s not my job, but providing they don’t screw that up it will all be fine.’

Pfizer’s vaccine needs to be stored at ultra-low temperatures, which makes trying to ship and distribute the shots a logistical headache.

The vaccine must be kept at -70C (-94F) which rules out storing it at most hospitals or pharmacies, where jabs are normally kept and administered.

Pfizer’s shot will likely need to be stored in laboratories or specialist hospitals. To transport it around the country will also require expensive refrigerated lorries.  

The UK will also only receive 10million doses of Pfizer’s vaccine – the only one so far to have preliminary phase three trial results – by Christmas, which is enough for five million Brits because the shot needs to be administered a second time after 21 days to work properly. It means only a select few groups will get access to the vaccine in 2020 and draconian lockdown rules will need to stay in place well into next year. 

Mr Hancock said vulnerable Brits could be among the first citizens in the world to get access to the vaccine because of the leg work that has already been put in. As well as pre-ordering 40million doses, the MHRA has had Pfizer’s jab under a rolling review, meaning the regulator has been monitoring data from the studies in real-time.

Mr Hancock said this means it could take just days for the MHRA to approve the vaccine once the full data is published later this month – a process which takes years under normal circumstances.

The Health Secretary told Sky News: ‘I’ve asked the NHS who are supported by the armed services in this – but the NHS very much leading this effort for deploying the vaccine – I’ve asked them to be ready from the start of December.

‘And, of course, there are many hurdles that still need to be gone over and we haven’t seen the full safety data and obviously that is critical and we won’t deploy a vaccine unless we can be confident in its clinical safety.

‘But we also do need to be ready should a vaccine be licensed and get through all those hurdles and ready to roll it out.’

Mr Hancock said there were still a few key hurdles to overcome before the ‘vast task’ of vaccination could begin, including regulatory approval of the new Pfizer/BioNTech vaccine and assessment of its safety data. 

He added it had always been his expectation that most people will not get a jab until 2021.

‘We’ve always been clear that our central expectation for the rollout of a vaccine should a vaccine come good… the central expectation of the bulk of the rollout and deployment has always been in the first part of 2021,’ he said.

The Health Secretary said that once a vaccine becomes available, it will be delivered through care homes, GPs and pharmacists, as well as ‘go-to’ vaccination centres set up in venues such as sports halls.

He told BBC Breakfast: ‘We will be working across the NHS with the support of the armed forces seven days a week, over weekends, over bank holidays, to get this rolled out into people’s arms as quickly as possible.’

He said the exact model would depend on which vaccine was adopted, with Oxford University and AstraZeneca expected to release results of their vaccine shortly.

‘The Pfizer vaccine needs to be held at minus 70C until the last few hours before it is deployed, which obviously makes things more complicated,’ Mr Hancock said. The AstraZeneca vaccine is a bit easier to deploy logistically.’

Because Pfizer’s vaccine must be stored at the ultra-low temperatures, this could make it difficult for GP clinics and care homes to store.

To combat the issue, the American drug maker has designed a special suitcase-sized box to help deliver the vaccines. 

The vaccines must be stored in dry ice – a solid form of carbon dioxide which mixed with other substances can create a cold ice bath of around minus 78C.

And, according to leaked Pfizer documents, the suitcases containing the doses can only be opened for a minute at time and not more than twice a day, the Times reports, making it difficult to supply the doses to patients. 

The AstraZeneca/Oxford University jab can be stored at room temperature, making it much easier to store and distribute.

Oxford’s vaccine is expected to report its first results next week, MailOnline understands. It means the actual approval process for the jab could begin weeks ahead of Pfizer — offering Britain a second shot of getting a jab before Christmas.

Mr Hancock said both vaccine would not be required for children and that uptake would be voluntary.

‘We are not proposing to make this compulsory – not least because I think the vast majority of people are going to want to have it,’ he said.

Mr Hancock urged people not to drop their guard and stop following the rules around social distancing, saying coronavirus is ‘still a deadly disease’.

He added he was ‘not going to put a date on’ when life may get back to normal after Sir John Bell, regius professor of medicine at Oxford University and a member of the Government’s vaccine taskforce, said he was confident people could look forward to a return to normal life by the spring.

‘This is promising news, but it is one step of many that we need to take to get out of this and to tackle this pandemic once and for all,’ Mr Hancock added.

The Cabinet minister acknowledged there was ‘enormous complexity’ in storing and administering the Pfizer vaccine, which needs to be kept in cold storage.

‘Also, you can’t take it out of that freezer more than four times on its journey from the manufacturing plant into the arm of patients… so that brings its complications,’ he said.

‘I’m sure that the NHS is going to rise to this challenge of deployment, and we’ve been working on it for four months now.

‘What I’d say is this is a promising step, but there’s many steps still to come.’

Regarding progress on the vaccine from Oxford University and AstraZeneca, Mr Hancock said he did not know when their first data would be released.

‘We’re not exactly sure when further news will come from the Oxford trial,’ he said. ‘But we’re working again to ensure that that can be deployed, should it come off.

‘I’m sure that the NHS is going to rise to this challenge of deployment, and we’ve been working on it for four months now.

‘What I’d say is this is a promising step, but there’s many steps still to come.’

Regarding progress on the vaccine from Oxford University and AstraZeneca, Mr Hancock said he did not know when their first data would be released.

‘We’re not exactly sure when further news will come from the Oxford trial,’ he said.

‘But we’re working again to ensure that that can be deployed, should it come off.’

The UK Government has ordered 40 million doses of the Pfizer vaccine – enough for about a third of the UK population.

It expects 10 million of these doses to arrive in the UK before the end of this year, with people given to doses, 21 days apart.

Pfizer is manufacturing its own vaccines and will ship them to the UK already made. 

On the other hand, Oxford University’s jab is being made in the UK.

Kate Bingham, head of Britain’s vaccine taskforce, has warned the country has the capacity to manufacture 4million doses of Oxford’s shot by the end of the year. 

Oxford’s jab, like Pfizer’s, has to be taken via two doses within weeks of each other to have the biggest effect.

It means two million additional Brits could get access to the university’s shot before the end of the year. 

Meanwhile, a vaccine being developed by US pharmaceutical giant Moderna has been earmarked as a third candidate that could be ready before 2021.

The vaccine is in phase three trials with 30,000 participants to assess whether it works in real-world scenarios.

It was put under a rolling review by the MHRA – the same process which will also help speed up the rollout of vaccines by Pfizer and Oxford.

In terms of who will get access to the three vaccines first, minutes released in November on the JCVI’s meetings spoke of problems with infection in the top care home setting on the list. 

It stated: ‘It was noted that outbreaks of acute respiratory infections in care home had been a feature of the epidemic from the beginning.

‘Genomic evidence indicated multiple introductions into care homes. More recently care homes had accounted for a smaller proportion of incidents reported to Health Protection Teams (HPTs), with increases seen in educational settings, workplaces and other settings.’ 

The suggested priority list for the vaccine jumped to the forefront of public attention yesterday after pharmaceutical giant Pfizer, working with German biotech company BioNTech, announced their mRNA-type vaccine was more than 90 per cent effective in preventing Covid-19.

It has been tested on 43,500 people in six countries and no safety concerns have been raised.

And now Pfizer plans to apply to the US regulator the Food and Drug Administration (FDA) for emergency approval to use the vaccine by the end of the month.

Its own analysis was carried out after 94 confirmed cases of Covid-19 were found among those taking part in the trial.

The UK has secured 40 million doses of the Pfizer/BioNTech vaccine – the first agreement the firms signed with any government.

It is thought people will need two doses, meaning not enough shots have been secured for the entire UK population.

However, it is likely other vaccines will announce results from their clinical trials shortly. 

All vaccines undergo rigorous testing and have oversight from experienced regulators.

Some believe mRNA vaccines are safer for the patient as they do not rely on any element of the virus being injected into the body.

mRNA vaccines have been tried and tested in the lab and on animals but the coronavirus vaccine will be the first one licensed for use in humans.

The human trials of mRNA vaccines – involving tens of thousands of people – have been going on since early 2020 to show whether it is safe and effective.

Pfizer will continue to collect safety and long-term outcomes data from participants for two years.

The Welsh Government confirmed today that high-risk groups, which is in line with Matt Hancock’s promise the jab will be distributed evenly through the UK.  

A Welsh Government spokesman said on Tuesday: ‘Planning for the delivery of a potential Covid-19 vaccine in Wales is well under way.

‘This includes organising the logistics for transporting the vaccine, identifying suitable venues for vaccinations to take place and ensuring that healthcare professionals are available and trained to administer the vaccines.

‘There will be limited supplies of a vaccine at first, so it will be offered to those at highest risk. The vaccines need to pass final safety checks, but if this occurs we will begin to immunise in December alongside other UK nations.

‘Health and social care workers, care home residents and staff have been prioritised to receive a vaccine first, with roll-out to older people in age bands from next year.’

At Monday’s Welsh Government press briefing, First Minister Mark Drakeford said he welcomed the early reports about the success of Pfizer’s coronavirus vaccine.

‘It is good news, of course, if any of the vaccines in trial are making progress,’ Mr Drakeford said.

‘We will want to see the nature of any vaccine, how much protection it offers people for how long, but of course any vaccine that is emerging strongly from trials is to be welcomed because it will offer some new possibilities in the future.’

The UK Government is leading procurement of possible vaccines on behalf of the whole UK, with each nation taking a share in proportion to its population and choosing how it is circulated.

It comes after Brazil suspended clinical trials of a Chinese-developed Covid-19 vaccine after an ‘adverse incident’ involving a volunteer recipient.

The setback for CoronaVac, developed by China‘s Sinovac Biotech, came as US pharmaceutical giant Pfizer said its own vaccine candidate had shown 90 per cent effectiveness – sending global markets soaring and raising hopes of an end to the pandemic.

Sinovac Biotech on Tuesday stood by its creation, saying: ‘We are confident in the safety of the vaccine’.

The Brazilian regulator Anvisa said it had ‘ruled to interrupt the clinical study of the CoronaVac vaccine after a serious adverse incident’ involving a volunteer recipient on October 29. 

It said it could not give details on what happened because of privacy regulations, but that such incidents included death, potentially fatal side effects, serious disability, hospitalization, birth defects and other ‘clinically significant events.’

Sinovac, however, said the incident was ‘not related to the vaccine’, adding it will ‘continue to communicate with Brazil on this matter’.

The public health center coordinating the trials of the vaccine in Brazil, the Butantan Institute, said it was ‘surprised’ by Anvisa’s decision.

The institute ‘is investigating in detail what happened’ and ‘is at the Brazilian regulatory agency’s disposal to provide any clarification necessary on any adverse incident the clinical trials may have presented,’ it said. 

Everything you need to know on Pfizer’s breakthrough jab

BySam Blanchard Senior Health Reporter For Mailonline

The global race to find a Covid-19 vaccine took a leap forward today when pharma companies Pfizer and BioNTech claimed their jab is 90 per cent effective.

Hopes that the pandemic could come to an end surged, along with stock markets across the world, as the firms became the first to report results from large-scale clinical trial and hailed today ‘a great day for science and humanity’.

The UK has already bought 40million doses of the jab and a quarter of them could be ready to go before the end of the year, and cautious scientists admit the results are ‘excellent’ and ‘really impressive’ – with one even claiming Britain could be back to normal by spring 2021.

Here, MailOnline explains everything you need to know about the vaccine: 

WHAT DO THE NEW TRIAL RESULTS SHOW? 

Pfizer and German partner BioNTech said that 94 people in a trial of more than 43,000 have so far tested positive for Covid-19, and that over 90 per cent of those did not receive the real vaccine.

This suggests the vaccine is 90 per cent effective and that no more than eight out of those 94 people actually received the real jab. 

Most of the people who tested positive were in the placebo group, where people are given a fake vaccine so that what happens to them can be compared with those who get the real thing. 

The companies did not reveal the exact split of how many people had had the vaccine and how many had not. 

The results were revealed in a corporate press release, which is not considered transparent enough for independent review, but they will be published in full later this year when the study is more complete.    

This phase of the trial will continue until at least 164 participants have tested positive, the researchers said.

While previous studies have been extremely promising – suggesting, for example, that various vaccines boosted the immune system’s response to Covid – this is the first time any jab has been shown to actually ward off the virus. 

That the Pfizer jab is 90 per cent effective is far better than scientists dared hope. 

WHAT DOES THAT MEAN FOR ME?

The general public will not benefit from the vaccine – if it is approved – for weeks or months to come, but today’s results mean there is a ray of hope that the pandemic could end.

Coronavirus cannot yet be stopped without a vaccine, and one that prevents infections or at least reduces the risk of death could spell the end of social distancing.

In the UK, officials have bought 40million doses of the vaccine and they could be available to the most vulnerable people within months if the study ends well.  

WHEN COULD IT BE READY TO GIVE TO THE PUBLIC?

Pfizer and BioNTech have said they will try to apply to the Food and Drug Administration in the US for approval within the next month, provided their final results are as positive as today’s announcement suggests.

This is because Pfizer is an American company, based in New York. BioNTech is a German company so it is likely the same procedure will be followed in the European Union. 

It will then be a question of how long it takes regulators to decide, and of how long delivering all the doses takes if it is approved, but it could be just weeks into December.

Before the vaccine is given to millions of Britons, it must be first be approved by the regulatory body — the MHRA, which has already launched a rolling review of all existing data so it can be fast-tracked through the process when the drug giant eventually submits it for approval.  

The UK now has the power to approve its own vaccine without waiting for a licence from Europe, because of new laws passed during the pandemic, or an EU approval would also allow Britain to use the jab. 

Kate Bingham, chief of the UK’s vaccines taskforce, said last week that it was possible the jab could be ready in Britain before Christmas.

She said there was a ‘possibility of being ready before the end of the year’.

HAS THE UK ALREADY GOT DOSES OF THE VACCINE?

Downing Street today said it has ordered 40million doses of the double-dose vaccine, which would be enough to give to 20million people. 

Kate Bingham said last week that 10million doses of the Pfizer vaccine could be available in Britain by the end of year.

It means that, at the absolute most, only 10million Brits will receive the vaccine by Christmas, but the vaccine is given in two shots so this could actually be five million.

A further 30million doses would then be produced and sent to Britain next year – the timescale for this is not yet clear.  

HOW DOES THE VACCINE WORK? 

The jab is known as a messenger RNA (mRNA) vaccine, which uses genetic code from the virus to provoke the immune system.  

Traditional vaccines tend to use damaged or destroyed versions of the real virus to achieve the same effect – if this one works, it will be the first mRNA jab ever to be proven in humans. 

The vaccine is made of lab-generated genetic material which is created to imitate what scientists have found inside the coronavirus. 

The genetic material (mRNA) is then injected into the body inside a fatty molecule. 

The genes are specifically chosen to code for the ‘spike’ protein on the outside of the coronavirus, which are what the virus uses to bind to human cells and infect them.

When the molecules get into the body, they deliver the mRNA into living cells and trick the body into making its own copies of the spike protein.

When these appear in the bloodstream they trigger the immune system in the same way that the real virus would, although the effects are milder because there are no actual viruses driving the infections, so the situation is under the body’s control.

In the process, the immune system learns how to recognise and destroy the spikes so that when it encounters them for real it can kill the virus before it causes Covid-19.

IS IT SAFE?

Pfizer and BioNTech say they have not encountered any safety issues during their trials so far, which have been going on for six months.

This suggests with a good degree of confidence that the vaccine is safe for humans at least in the short term. 

Long-term safety can only be proven when huge numbers of people have had the vaccine and had their health tracked for years or even decades afterwards, so scientists cannot yet be 100 per cent sure that no side effects will ever appear.

However, the current phase three trial includes more than 43,000 people from different backgrounds all over the world, all of whom are being closely monitored after having the vaccine.

If people suffer side effects of the vaccine that are more common or more severe than in the placebo group – who received a fake vaccine for comparison – this will be investigated in detail by the researchers.

Pfizer and BioNTech will not be given permission to distribute the jab without showing independent regulators that they have concrete data to prove the jab is as safe as possible. 

Regulators will not accept a licensing submission until at least half the people in the trial have been vaccinated for at least two months. That data is expected in a fortnight. Only then will the true safety profile be known. 

WHAT ARE SCIENTISTS STILL TESTING FOR?  

The trial is still going and will likely not end completely for years to come, because the more data scientists have, the more confident they can be about their results.

In the short term, the researchers must continue to gather safety data and proof that the vaccine is actually working.

The team said they will keep the current phase of the trial open until at least 164 people have been infected with the coronavirus.

They will then compare the infection rate in the vaccine group to that of the placebo group, who got a fake vaccine, to see how much of a difference the jab makes.

They will want to see that significantly fewer people got sick after having the jab, compared to people who had the fake one. Early data suggests this is the case. 

Safety data is still being collected, too. 

Before Pfizer and BioNTech can apply to US regulators for permission to use the jab on the public, they must produce two months’ worth of data for at least half of the study’s 38,955 participants who have had both doses of the vaccine.

This data must show that the vaccine can be given safely to large numbers of people without any serious side effects. 

Vaccines are not ruled out by any side effects, and regulators will be looking for proof that the benefits of the jab outweigh any potential risks.  

WHO WILL GET THE JAB FIRST IN THE UK?

Care home residents and staff will be the first to get a Covid-19 vaccine when one is approved, according to Government advice published in late September. 

Everyone over the age of 80 and NHS staff will be second in line, guidance from the Joint Committee on Vaccination and Immunisation says. 

Those over 75 will be next in the queue, followed by over-70s, over-65s and high-risk adults under 65 with diseases like cancer.

They will be followed by moderate risk adults under 65 – including diabetics and asthmatics.

Over-60s will be next, with over-55s and over-50s the final priority groups.

The general population will be last to get their hands on a vaccine and they will most likely be prioritised based on age or underlying conditions. 

HOW WILL THE VACCINE BE ADMINISTERED IN THE UK?

The UK Government has announced that it is expanding the group of people who will be able to administer vaccines, as well as potentially setting up walk-in or drive-in centres in public locations such as car parks outside GP surgeries.

Physios and paramedics will be trained to deliver Covid-19 jabs to help the NHS carry out its mass vaccination programme through the winter.

Currently, only doctors, pharmacists and some nurses are legally allowed to administer vaccines in the UK.

But new laws passed in October grant more health workers – including midwives and even medical students – to be able to inoculate members of the public.

They are currently being put through ‘robust training’ according to the Government, which it says will ‘save thousands of lives by increasing access to vaccines against killer disease’.  

ARE THERE LOGISTICAL PROBLEMS WITH BUYING SO MUCH VACCINE?

Experts have raised concerns that storing the vaccine in Britain might be difficult.

Pfizer and BioNTech’s vaccine may have to be stored at temperatures below -70°C (-90°F) to make sure that it remains stable and can still work when injected.

If they rise to temperatures higher than this at any point between the lab and wherever they are administered from they could become chemically unstable and fail to work properly.

Dr Michael Head, global health expert at the University of Southampton, said: ‘It has been reported that the vaccine requires storage at -70 degrees centigrade, and that is not necessarily routinely available in most health centres even in the UK, let alone globally.’

And Dr Al Edwards, a professor of biomedical technology at the University of Reading, added: ‘The task of producing substantial amounts of a new vaccine and disturbing widely will be a challenge, not least for this particular formulation where ensuring that it can be appropriately frozen until needed and must not be allowed to thaw in transit.’ 

WHAT DOES THIS MEAN FOR LOCKDOWNS AND SOCIAL DISTANCING?

Social distancing and lockdowns – known as ‘non-pharmaceutical interventions’ – will not come to an end as soon as a vaccine is proven to work.

It would take months to vaccinate enough people for it to actually impact on the spread of coronavirus among the public, especially if people who are more likely to be in care homes or shielding are the first ones to receive the jab.

Experts do not know exactly what proportion of people will need to be vaccinated to develop herd immunity, which is when the virus cannot cause outbreaks any more. 

It is thought to be higher than two thirds, which means over 42 million people will need to have a working vaccine. 

The UK has not ordered enough of Pfizer’s vaccine to rely on that completely – although more could likely be bought in future – but it has ordered more than 300million doses of other vaccines that could work.

Sir John Bell, regius professor of medicine at the University of Oxford, said on BBC Radio 4 this afternoon: ‘I am really delighted with this result – it shows that you can make a vaccine against this little critter. Ninety percent is an amazing level of efficacy.

‘It rolls the pitch for other vaccines because I can’t see any reason now why we shouldn’t have a handful of good vaccines.’

Asked if people could look forward to a return to normal life by the spring, Sir John replied: ‘Yes, yes, yes, yes. I am probably the first guy to say that but I will say that with some confidence.’

WHAT DO SCIENTISTS SAY ABOUT THE PROGRESS?

Scientists from across the UK have today praised the results of the Pfizer Covid-19 vaccine, saying it could spell an end to the pandemic.

Oxford University’s Professor Peter Horby, who led the team that proved the steroid dexamethasone could save dying coronavirus patients, said: ‘This news made me smile from ear to ear.’

While Dr Paul Hunter, an infectious disease expert at the University of East Anglia, told MailOnline he was ‘really pleased about this result’.

‘You can almost begin to start seeing the light at the end of the tunnel. I just hope it’s not an oncoming train.’

Despite offering a glimmer of hope, other scientists have said the results are still only early indications, so it is important to not get carried away.

Professor Brendan Wren, from the London School of Hygiene & Tropical Medicine, said: ‘A 90 per cent efficacy for a phase three trial is excellent for a new vaccine that could make a huge difference.

‘But more confirmatory safety and efficacy studies are required.

Professor Eleanor Riley, an immunology and infectious disease expert at the University of Edinburgh, added: ‘At face value, this is exceptionally good news.

‘However, the full data set on which the claim is based has not yet been released and so we don’t know exactly what has been found.’  

Sir John Bell, medicine professor at the University of Oxford, welcomed the news but said the distribution of the vaccine would be ‘challenging’.

‘They will obviously start in the US – that’s probably appropriate,’ he told BBC Radio 4’s The World at One. ‘BioNTech is a German company so there will be, I am sure, doses made available for Europe.

‘The UK has done a pre-approval agreement to purchase up 30 million doses of this vaccine, so we are very well prepared to get access to this vaccine when it becomes available.

‘The manufacturing challenges are not small, so people need be ready to wait a bit to get it.’

HOW DOES THE OXFORD UNIVERSITY JAB DIFFER?  

Oxford’s is an adenovirus vector vaccine, which contains a weakened version of a chimpanzee cold virus that has been genetically changed to trigger the production of immune cells – antibodies and T-cells.

COULD MORE THAN ONE VACCINE BE USED BY THE UK? 

Definitely. The Government has orders in place for 300 million doses from six different companies. If more than one is approved, the joint virus committee will decide which people will get which vaccines, depending on the trial data for different age groups. It is unlikely that two vaccines will be used in combination for the same person, at least in the near future – more research will be needed to see if that boosts protection or not.

DOES THIS MEAN AN END TO THE CURSED CORONAVIRUS?

No – and the Government was keen last night to stress adherence to social distancing rules. But if the vaccine is as effective as the results suggest it may mean an end to this phase of the pandemic. Some scientists last night suggested it might even mean a return to normality by spring.

HOW MANY PEOPLE NEED TO BE VACCINATED BEFORE WE TRULY KILL OFF COVID? 

To see off the virus we need to achieve ‘herd immunity’, which will mean the virus can no longer spread from person to person and simply dies out. In normal circumstances every person with Covid affects three others – giving the infamous R-rate of 3. For the virus to die out the R rate needs to be reduced to 1. In order to achieve that, 60 per cent of the population would need to be vaccinated. Experts believe that if one or two more vaccines come through – and if they have anything like the same potential – that will be achievable in a year.

HOW MUCH WILL IT COST?

The vaccine will be provided by the NHS for free. It is unclear how much the Government’s deal with Pfizer is worth, but the firm is reported to have struck deals with other nations for around £15 a dose.  

Yes, there are niggles… but this really is a historic day: Bacteriology professor HUGH PENNINGTON argues the discovery of a possible Covid-19 vaccine is as significant as development of atomic bomb during World War II

When I saw the newsflash about the vaccine yesterday, I was immediately reminded of another – and admittedly very different – scientific achievement.

The Manhattan Project in World War II led to the development of the atomic bomb.

Now whatever your view of the destructive use of nuclear weapons – and tragically more than 200,000 people died at Nagasaki and Hiroshima – it is widely accepted that without their deployment that conflict would have continued.

Hundreds of thousands of service personnel and civilians would have died, with more misery and suffering for millions worldwide. 

I believe that the global potential of this vaccine – to save lives and reduce suffering – is on a similar scale.

In both cases, researchers understood the basic science from the outset, but had to produce results fast while millions of lives hung in the balance.

What has been achieved from a standing start really is an incredible feat.

The fact that the new vaccine appears to give initial protection in 90 per cent of cases is better than even the greatest optimist could have predicted.

Of course, we have to understand that the crisis isn’t over yet. It’s still early days, these are interim results and trials are continuing. 

Nor was yesterday’s statement the result of a peer-reviewed paper in a scientific journal – instead a press release.

We are also some way off regulatory approval (in the US, Europe and the UK) for the new vaccine.

But that should not detract from the impact of the announcement.

The results are significant, for two reasons: firstly, because the vaccine appears to be effective, and secondly because there are to date no reports of side effects.

Given the urgency of the situation, I do not expect red tape to hold up proceedings. But I also expect the authorities to guard against recklessness.

This, after all, is a new kind of vaccine. It contains a fragment of the Covid-19 virus’ genetic material. 

This is inactive but can stimulate the production of protective antibodies. 

It represents a significant advance in molecular biology but, because it involves a novel delivery method, we don’t yet know how well it will work. It simply hasn’t been tried before.

It is also more complicated to administer than the flu vaccine, for example, which involves just a single dose. The Covid-19 vaccine will require two jabs, three weeks apart.

Immediately, that complicates the process and presents logistical problems for GP surgeries, hospitals and other sites, including schools and care homes, where the vaccine is administered. 

To make matters more difficult still, the vaccine has to be stored and transported in liquid nitrogen at a temperature of -70C, facilities beyond most hospital pharmacies and high street chemists.

The biggest unanswered question about the new vaccine is how long it will protect against Covid-19. Trials suggest it offers 90 per cent immunity but this may wane over time.

Flu jabs also give good initial protection but that declines over the course of a flu season to around 50 per cent. Will that prove to be the case with the Covid-19 vaccine?

We won’t know for a while but even at 50 per cent it will still offer life-saving protection, if those most at risk are among the beneficiaries: people over the age of 60 and those made vulnerable by other medical conditions. 

That would not only save lives but dramatically reduce hospital admissions – to the benefit of the NHS which would not then have to focus so much of its resources on Covid-19 victims at the expense of non-Covid patients.

While it represents a major breakthrough – the ‘toot of the cavalry’s bugle’ according to Boris Johnson – Pfizer/BioNTech is unlikely to be the silver bullet for Covid. 

But we should not forget that it is the only vaccine on the horizon. More than 170 projects worldwide are actively developing a coronavirus vaccine.

The first trial recognised by the World Health Organisation began back in the spring, just 60 days after Chinese scientists shared a breakdown of the Covid virus’ genetic sequence. 

Researchers at Oxford University working on the AstraZeneca Oxford vaccine have also announced that in preliminary tests it is inducing a safe immune response.

All of this builds on decades of painstaking research. The search for a flu vaccine began in earnest in the 1930s in the wake of the Spanish Flu pandemic which killed 50million people. 

Perseverance brought success from the 1950s onwards.

Now we have two pretty good preventatives for flu: a drop administered up the nose for children, and an injection in the arm for the over-65s with a booster that increases the immune response.

Inevitably, the new Covid-19 vaccine – indeed any new vaccine – will stir up the anti-vaxxers and conspiracy theorists. Propaganda against vaccines is nothing new. 

In the 19th century, cartoons circulated suggesting the smallpox jab caused people to grow horns like cows. Smallpox has now been eradicated, and I’ve never met any humans with horns.

As ever, the best response to such critics is for medical science to keep their methodology and ethical standards as high as possible.

The rewards that come with an effective vaccine will be great – soaring company profits and acclaim for individual scientists. Perhaps Nobel Prizes beckon.

But it is the impact globally that counts: untold lives saved, economies resurrected, pubs, bars and restaurants buzzing again, churches and theatres open once more… and a nation where it’s possible for us to see our friends and loved ones without restriction again.

The thought of that is like the sun coming out.

Hugh Pennington is Emeritus Professor of Bacteriology at the University of Aberdeen